Pressure BioSciences (OTCQB: PBIO) (“PBI”) today unveiled
its intention to further commit substantial financial and operational support
to fast-track the development of its Ultra Shear Technology (“UST”) platform,
effective immediately. The company plans to pursue commercialization of its
technology platform into major new markets. “We have committed approximately
2,000 sq. ft. of recently acquired space to our Ultra Shear Technology platform
development and nanoemulsions commercialization program. We view this as an
extraordinary opportunity that offers a range of major new market segments for
PBI. We have instructed our Engineering and R&D personnel to finalize the
development of our first-generation UST instrument and to make the generation
of proof-of-principle nanoemulsion data for multiple product areas their top
priority. We have also reallocated significant time and resources from several
staff members to the UST platform development program,” Pressure BioSciences
President and CEO Richard T. Schumacher stated in the news release. “Finally,
we are rapidly accelerating discussions with multiple U.S., Canadian, and other
companies, academic organizations, and government agencies that have expressed
a strong desire to collaborate with PBI and acquire access to our proprietary
UST process. We are on course to establish collaborative development projects
with multiple companies and research groups addressing different product and
market opportunities. These programs should lead to revenue-generating products
in the near future. We believe there are many industries that can benefit from
UST-produced nanoemulsions and that this can be an area of rapid and sizeable
growth for PBI moving forward.”
To view the full press release, visit http://ibn.fm/vTMNg
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of our pressure-based technologies in the following areas: (1) the use of
our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into
the biologics contract research services sector, and (2) the use of our
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible
fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized,
extended shelf-life or room temperature stable low-acid liquid foods that
cannot be effectively preserved using existing non-thermal technologies. For
more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
